Kidney International

Article	Citations
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases	924
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease	527
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease	423
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases	423
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe	378
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	259
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy	223
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease	210
Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference	207
Outcomes of patients with end-stage kidney disease hospitalized with COVID-19	205
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants	202
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease	196
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease	187
Molecular mechanisms and therapeutic targets for diabetic kidney disease	185
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule	174
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine	166
Semaphorin 3B–associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients	149
Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification	136
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy	127
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial	124
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference	123
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence	122
Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients	120
NELL1 is a target antigen in malignancy-associated membranous nephropathy	118
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains	114

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant	109
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice	108
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglob	108
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients	108
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease	105
Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients	103
Rationale and design of the Kidney Precision Medicine Project	102
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis	101
Occurrence of severe COVID-19 in vaccinated transplant patients	100
COVID-19 infection in kidney transplant recipients at the epicenter of pandemics	100
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)	98
ANCA glomerulonephritis after the Moderna COVID-19 vaccination	97
A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19)	96
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment	94
Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis	92
Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics	91
Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy	90
Allorecognition and the spectrum of kidney transplant rejection	88
Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis	88
IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)	85
A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination	84
Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine	83
A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death	83
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients	76
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action	75
Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study	73
Targeting inflammation to treat diabetic kidney disease: the road to 2030	72
De novo vasculitis after mRNA-1273 (Moderna) vaccination	69
Cystinuria: clinical practice recommendation	68
Is COVID-19 vaccination unmasking glomerulonephritis?	68
COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?	68
Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders	68
The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults	67
A practical guide to multiple imputation of missing data in nephrology	66
SARS-CoV-2 receptor networks in diabetic and COVID-19–associated kidney disease	64
Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy	64
Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	63
Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome	63
Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy	62
The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis	62
Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction	61
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function	60
A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis	59
IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine	59
Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy	58
Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease	58
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response	58
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection	58
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria	57
Exosome-based delivery of super-repressor IκBα ameliorates kidney ischemia-reperfusion injury	57

Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)	57
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment	56
Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation	56
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline	55
Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants	54
Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy	54
Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination	54
Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes	54
Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy	53
Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis	53
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction	53
Diagnosis and treatment of arterial hypertension 2021	51
Executive summary for China Kidney Disease Network (CK-NET) 2016 Annual Data Report	51
Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease	51
A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk	51
The lupus nephritis management renaissance	50
AI applications in renal pathology	50
A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?	50
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS	49
A Mendelian randomization study found causal linkage between telomere attrition and chronic kidney disease	48
Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms	48
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with	48
Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients	48
New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination	48
A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout	47
Atypical HUS relapse triggered by COVID-19	46
Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society	46
Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination	46
Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients	46
Targeting energy pathways in kidney disease: the roles of sirtuins, AMPK, and PGC1α	45
Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19	45
Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease	45
Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice	44
Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation	44
Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine	44
Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction	43
Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy	43
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients	43
Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendations	43
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2	42
A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass	42
Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment	42
Management of acute kidney injury in symptomatic multiple myeloma	42
Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost	42
The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease	41
Modulation of transforming growth factor-β-induced kidney fibrosis by leucine-rich ⍺-2 glycoprotein-1	41
Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism	40
An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis	40
Home dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	40
Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients	40
Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won	39
Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values	39
Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome	39
Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression	39
Human kidney organoids produce functional renin	39
Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine	39
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury	38
Cannabinoid receptor type 2 promotes kidney fibrosis through orchestrating β-catenin signaling	38
Acute rejection after anti–SARS-CoV-2 mRNA vaccination in a patient who underwent a kidney transplant	38
Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation	37
A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse	37
The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds	37
Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere	37
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	37
Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome	37
Deep learning identified pathological abnormalities predictive of graft loss in kidney transplant biopsies	37
Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis	36
Minimal change disease relapse following SARS-CoV-2 mRNA vaccine	36
Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity	36
A multicenter feasibility randomized controlled trial to assess the impact of incremental versus conventional initiation of hemodialysis on residual kidney function	35
Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant	35
Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy	35
Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis	35
The time of onset of intradialytic hypotension during a hemodialysis session associates with clinical parameters and mortality	35
A multicenter study to develop a non-invasive radiomic model to identify urinary infection stone in vivo using machine-learning	35
Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants	35
Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties	35
Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring	34
Receptor activator of NF-κB mediates podocyte injury in diabetic nephropathy	34
COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders	34

Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine	34
A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit for arteriovenous fistulas	34
SGLT-2 inhibition in IgA nephropathy: the new standard of care?	34
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy	34
Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine	34
Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination	34
Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery	33
Updating the International IgA Nephropathy Prediction Tool for use in children	33
Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	33
The spatially resolved transcriptional profile of acute T cell–mediated rejection in a kidney allograft	33
Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe	33
Global transcriptomic changes occur in aged mouse podocytes	33
COVID-19 in dialysis patients: outlasting and outsmarting a pandemic	32
Post-vaccinal minimal change disease	32
A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3	32
Simultaneous glomerular filtration rate determination using inulin, iohexol, and 99mTc-DTPA demonstrates the need for customized measurement protocols	32
The clinicopathologic spectrum of segmental membranous glomerulopathy	32
Best practices for correctly identifying coronavirus by transmission electron microscopy	32
The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease	32
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes	31
Rho GTPase regulatory proteins in podocytes	31
Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine	31
Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease	31
A case of membranous nephropathy following Pfizer–BioNTech mRNA vaccination against COVID-19	31
Decline and loss of anti–SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection	30
High rates of long-term renal recovery in survivors of coronavirus disease 2019–associated acute kidney injury requiring kidney replacement therapy	30
Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy	30
Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing	30
Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling	30
Type I interferon–related kidney disorders	30
Hemopexin accumulates in kidneys and worsens acute kidney injury by causing hemoglobin deposition and exacerbation of iron toxicity in proximal tubules	30
Highly multiplexed immunofluorescence of the human kidney using co-detection by indexing	29
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer	29
From kidney injury to kidney cancer	29
Comparison of BNT162b2 (Pfizer–BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients	29
Kidney repair and regeneration: perspectives of the NIDDK (Re)Building a Kidney consortium	28
Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease	28
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model	28
Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife	28
The emerging field of non–human leukocyte antigen antibodies in transplant medicine and beyond	28
An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes	28
Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys	28
Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target	28
EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients	28
A prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors	27
Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy	27
Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry	27
Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency	27
Mendelian randomization to assess causality between uromodulin, blood pressure and chronic kidney disease	27
Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period	27
Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis	27
Insulin-like growth factor binding protein 7 promotes acute kidney injury by alleviating poly ADP ribose polymerase 1 degradation	27
A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy	26
Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis	26
A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients	26
Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone	26
Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors	26
Phosphoglycerate mutase 5 initiates inflammation in acute kidney injury by triggering mitochondrial DNA release by dephosphorylating the pro-apoptotic protein Bax	26
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy	26
Membranous nephropathy following anti–COVID-19 mRNA vaccination	25
HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients	25
Basic principles and new advances in kidney imaging	25
The state of the global nephrology workforce: a joint ASN–ERA-EDTA–ISN investigation	25
Managing the symptom burden associated with maintenance dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference	25
A small molecule inhibitor of the chloride channel TMEM16A blocks vascular smooth muscle contraction and lowers blood pressure in spontaneously hypertensive rats	25
Clearly imaging and quantifying the kidney in 3D	24
Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies	24
Uremic encephalopathy	24
The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis	24
Barriers to accessing essential medicines for kidney disease in low- and lower middle–income countries|	24
Genome-wide association study of serum metabolites in the African American Study of Kidney Disease and Hypertension	24
Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes	24
Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients	24
micro-RNA-486-5p protects against kidney ischemic injury and modifies the apoptotic transcriptome in proximal tubules	24
Does gouty nephropathy exist, and is it more common than we think?	24
Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease	24
Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations	24
Magnetic resonance imaging accurately tracks kidney pathology and heterogeneity in the transition from acute kidney injury to chronic kidney disease	24
A molecular circadian clock operates in the parathyroid gland and is disturbed in chronic kidney disease associated bone and mineral disorder	24
A reciprocal regulation of spermidine and autophagy in podocytes maintains the filtration barrier	23
Protein phosphatase 2Acα modulates fatty acid oxidation and glycolysis to determine tubular cell fate and kidney injury	23
Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care	23
Microbiome modulation after severe acute kidney injury accelerates functional recovery and decreases kidney fibrosis	23
A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease	23
Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2	23
Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection	23
Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis	23
Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease	23
Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease	23
Letter regarding “Minimal change disease relapse following SARS-CoV-2 mRNA vaccine”	23
Epithelial proliferation and cell cycle dysregulation in kidney injury and disease	23
National and international kidney failure registries: characteristics, commonalities, and contrasts	23
Ubiquitin-specific protease 11 promotes partial epithelial-to-mesenchymal transition by deubiquitinating the epidermal growth factor receptor during kidney fibrosis	23
A well-developed endolysosomal system reflects protein reabsorption in segment 1 and 2 of rat proximal tubules	23
Immune evasion in renal cell carcinoma: biology, clinical translation, future directions	22